


PRODUCT: RO5126766

ALTERNATE NAMES: Ro-5126766; Ro5126766; Ro 5126766; RO 5126766; RO-5126766; CH5126766; Ro 5126766; CH 5126766; CH-5126766; 3-[[2-[(Methylaminosulfonyl)amino]-3-fluoropyridin-4-yl]methyl]-4-methyl-7-[(pyrimidin-2-yl)oxy]-2H-1-benzopyran-2-one; 3-[[3-fluoro-2-(methylsulfamoylamino)pyridin-4-yl]methyl]-4-methyl-7-pyrimidin-2-yloxychromen-2-one

CATALOG#: B1705-5, -25

AMOUNT: 5 mg, 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₁H₁₈FN₅O₅S

MOLECULAR WEIGHT: 471.46

CAS NUMBER: 946128-88-7

APPEARANCE: Solid powder

SOLUBILITY: DMSO

PURITY: >98%

STORAGE: Dry, dark and at 4°C for short term (days to weeks) or at -20°C for long term. Protect from air and light.

DESCRIPTION: Ro5126766 (CH5126766) is a potent and selective dual RAF/MEK inhibitor. For SK-MEL-28, SK-MEL-2, MIA PaCa-2, and SW480 cell lines, the IC₅₀ is determined by WST-8 assay is 65, 28, 40, and 46 nM, respectively.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Honda K et al. Phase I and pharmacokinetic and pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. *Cancer Chemother Pharmacol*, 2013, 72(3): 577-584.
2. Ishii N et al. Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity. *Cancer Res*, 2013, 73(13): 4050-4060.

RELATED PRODUCTS:

- Gossypin (Cat. No. 2374-50, 250)
- GSK-2118436 mesylate (Cat. No. 2800-5, 25)
- GW-5074 (Cat. No. 2412-5, 25)
- PLX-4032 (Cat. No. 2235-5, 25)
- PLX-4720 (Cat. No. 2813-5, 25)
- B-Raf Inhibitor I (Cat. No. 2599-5, 25)
- TAK-632 (Cat. No. 2473-5, 25)
- ZM 336372 (Cat. No. 1789-1, 5)
- Doramapimod (Cat. No. 1954-5, 25)
- PD1834352 (CI-1040) (Cat. No. 1585-1, 5, 25)
- EZSolution™ PD184352 (Cat. No. 1871-1)
- PD325901 (Cat. No. 1643-2, 5, 25)
- PD98059 (Cat. No. 1666-5)
- EZSolution™ PD98059 (Cat. No. 1783-5)
- SB 203580 (Cat. No. 1712-1, 5)
- EZSolution™ SB203580 (1786-1)
- Sorafenib (Cat. No. 1594-25, 100)
- 7, 3', 4'-Trihydroxyisoflavone (1886-25, 100)
- U0126 (Cat. No. 1668-5)
- VX-702 (Cat. No. 1598-1, 5)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**